4th Edition Global Longevity Federation

Researchers identify a new molecular mechanism that could help design future therapies to treat Alzheimer’s disease

A research team at the Institute of Neurosciences of the University of Barcelona (UBneuro) has led a study describing a new molecular mechanism that affects RNA processing and alters the process of protein synthesis in the brains of Alzheimer’s patients. The study, which has been carried out in post-mortem samples of patients and in animal models of the disease, will boost the design of future therapies to address the treatment of this dementia and other neurological disorders.Readmore

Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases

New strategic partnership leverages the power of the Dyno platform, enabling Roche to advance next-generation AAV gene therapies across multiple targets – Dyno to receive US$50 million upfront cash with the potential to earn over US$1 billion in milestones plus royalty paymentsReadmore

Common drug shows promise in extending lifespan. Scientists say mifepristone, used in cancer and reproductive care, could pave the way for anti-aging treatments.

New research from biologists at the USC Dornsife College of Letters, Arts and Sciences reveals that mifepristone, a drug best known for its use for ending early pregnancies, might also extend lifespan. The findings could pave the way for anti-aging treatments.Readmore

Donations from Didier Coeurnelle enable next phase of Robust Mouse Rejuvenation research program

Longevity Escape Velocity Foundation (LEVF) today welcomes two very generous donations from long-time supporter of longevity research and activism, Didier Coeurnelle. The first donation is 200,000 euros (approximately 220,000 US dollars). The second donation, of up to another 200,000 euros, is dependent on LEVF receiving matching gifts from other donors from 1st October until the end of the month (October 31st).Readmore